Shares of Applied Therapeutics are down 11% at $6.07 afterhours after the company announced that the FDA has extended the review period for the New Drug Application for govorestat for the treatment of Classic Galactosemia by three months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics initiated with an Outperform at RBC Capital
- Applied Therapeutics files to sell 14.29M shares of common stock for holders
- Largest borrow rate increases among liquid names
- Applied Therapeutics Reveals Strategy and Positive Trial Update